ImmunoCellular Therapeutics Announces Webcast Presentation at Rodman & Renshaw 10^th Annual Healthcare Conference

LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (OTCBB:IMUC) (IMUC), a biotechnology company, today announced that the company’s president and chief executive officer, Manish Singh, Ph.D., will make a company presentation at the Rodman & Renshaw 10^th Annual Healthcare Conference. The presentation will be webcast and will occur at 4:55 p.m. EST on Tuesday, November 11, 2008 at the New York Palace Hotel in New York City.

The presentations will be audio webcast live and available for replay from IMUC’s website, www.imuc.com.

IMUC is a Los Angeles-based clinical-stage company that is developing immune based therapies for the treatment of brain and other cancers. IMUC's lead product candidate—a dendritic cell-based vaccine for treating brain tumors—is currently being evaluated in a Phase I clinical trial. The company’s “off the shelf” therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is expected to enter clinical trials during the second quarter of 2009. IMUC is in pre-clinical development of a monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit www.imuc.com.